Scopus Biopharma Stock Return On Equity
Scopus Biopharma fundamentals help investors to digest information that contributes to Scopus Biopharma's financial success or failures. It also enables traders to predict the movement of Scopus OTC Stock. The fundamental analysis module provides a way to measure Scopus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scopus Biopharma otc stock.
Scopus |
Scopus Biopharma OTC Stock Return On Equity Analysis
Scopus Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Scopus Biopharma Return On Equity | -15.6 |
Most of Scopus Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scopus Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Scopus Biopharma has a Return On Equity of -15.596. This is 34.94% lower than that of the Healthcare sector and 57.22% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Scopus Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scopus Biopharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics of similar companies.Scopus Biopharma is currently under evaluation in return on equity category among its peers.
Scopus Fundamentals
Return On Equity | -15.6 | ||||
Return On Asset | -4.61 | ||||
Current Valuation | 1.18 M | ||||
Shares Outstanding | 21.09 M | ||||
Shares Owned By Insiders | 50.66 % | ||||
Shares Owned By Institutions | 2.15 % | ||||
Number Of Shares Shorted | 23.77 K | ||||
Price To Book | 2.42 X | ||||
EBITDA | (26.18 M) | ||||
Net Income | (26.95 M) | ||||
Cash And Equivalents | 1.16 M | ||||
Cash Per Share | 0.05 X | ||||
Total Debt | 2.54 M | ||||
Debt To Equity | 0.61 % | ||||
Current Ratio | 0.31 X | ||||
Book Value Per Share | (0.26) X | ||||
Cash Flow From Operations | (11.42 M) | ||||
Short Ratio | 0.22 X | ||||
Earnings Per Share | (1.51) X | ||||
Target Price | 12.0 | ||||
Beta | 1.16 | ||||
Market Capitalization | 2.17 M | ||||
Total Asset | 8.19 M | ||||
Z Score | -9.9 | ||||
Net Asset | 8.19 M |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |